Our lead oncology asset is nominated for Best Biomedical Product at Prix Galien Bridges Awards, recognizing its potential in advancing cancer therapeutics.

Published on

November 19, 2025

In the media

Our lead oncology asset is nominated for Best Biomedical Product at Prix Galien Bridges Awards, recognizing its potential in advancing cancer therapeutics.

About 91��ϳ��Ƭ Therapeutics

‍

91��ϳ��Ƭ Therapeutics is a clinical-stage biotech company advancing novel antigen modulation technology to guide the immune system. Our approach modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. We are progressing first-in-class antigen modulators to treat people living with 91��ϳ��Ƭ, autoimmune disorders, and infectious diseases.

‍

91��ϳ��Ƭ is headquartered in Oxford, UK.

‍

More information: Website |

‍

Media enquiries

Patrick White, Head of Communications

+44 (0)1235 644 970

patrick.white@gwt.bio

‍

All news

Discover how our therapies are reshaping treatment for various diseases and conditions.

Our approach

91���ϳ���Ƭ

Our lead oncology asset is nominated for Best Biomedical Product at Prix Galien Bridges Awards, recognizing its potential in advancing cancer therapeutics.

Discover how our therapies are reshaping treatment for various diseases and conditions.

Harnessing antigen modulation to empower T cells against diseases.

91��ϳ��Ƭ